Evidence map›Paper›PMID 35380053›Full record

Trial reportStroke2022

Magnesium Sulfate and Hematoma Expansion: An Ancillary Analysis of the FAST-MAG Randomized Trial.

Andrew M Naidech, Kristina Shkirkova, Juan Pablo Villablanca, Nerses Sanossian, David S Liebeskind, Latisha Sharma, Mark Eckstein, Samuel Stratton, Robin Conwit, Scott Hamilton and 2 more

Registry-linked trialOpen access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Stroke, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00059332 (Field Administration of Stroke Therapy-Magnesium Trial), which is not on this map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00059332 phase3completednot on this map

Field Administration of Stroke Therapy-Magnesium Trial: A Randomized, Double-Blind, Placebo Controlled Trial of Neuroprotective Magnesium Sulfate Therapy for Acute Stroke Initiated Within 2 Hours of Onset by Paramedics in the Field

TypeinterventionalSponsorJeffrey L. SaverRan2005 to 2013Enrolled1,700ConditionsCerebrovascular AccidentArmsMagnesium Sulfate, Normal Saline
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 2 countries.

Andrew M NaidechDepartment of Neurology, Northwestern Medicine, Chicago, IL (A.M.N.).ORCID 0000-0003-1065-5417
Kristina ShkirkovaDepartment of Neurology, University of California at Los Angeles (K.S., J.P.V., N.S., D.S.L., L.S., S.S., J.L.S.).ORCID 0000-0002-9288-4258
Juan Pablo VillablancaDepartment of Neurology, University of California at Los Angeles (K.S., J.P.V., N.S., D.S.L., L.S., S.S., J.L.S.).
Nerses SanossianDepartment of Neurology, University of California at Los Angeles (K.S., J.P.V., N.S., D.S.L., L.S., S.S., J.L.S.).ORCID 0000-0002-8218-9518
David S LiebeskindDepartment of Neurology, University of California at Los Angeles (K.S., J.P.V., N.S., D.S.L., L.S., S.S., J.L.S.).ORCID 0000-0002-5109-8736
Latisha SharmaDepartment of Neurology, University of California at Los Angeles (K.S., J.P.V., N.S., D.S.L., L.S., S.S., J.L.S.).ORCID 0000-0003-4132-2260
Mark EcksteinDepartment of Emergency Medicine, University of Southern California, Los Angeles (M.E.).
Samuel StrattonDepartment of Neurology, University of California at Los Angeles (K.S., J.P.V., N.S., D.S.L., L.S., S.S., J.L.S.).ORCID 0000-0002-2505-115X
Robin ConwitNational Institutes of Neurological Diseases and Stroke, Bethesda, MD (R.C.).ORCID 0000-0001-7650-6698
Scott HamiltonDepartment of Neurology, Stanford University, Palo Alto, CA (S.H.).
Jeffrey L SaverDepartment of Neurology, University of California at Los Angeles (K.S., J.P.V., N.S., D.S.L., L.S., S.S., J.L.S.).ORCID 0000-0001-9141-2251
FAST-MAG Investigators and Coordinators
Norwegian Womens Public Health Association · NONational Institute of Neurological Disorders and Stroke · USNorthwestern Medicine · USPalo Alto University · USUniversity of Southern California · US

Funding

Field Administration of Stroke Therapy-Magnesium Trial (FAST-MAG)U01NS044364 · NINDS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SAVER, JEFFREY L · 2003 to 2013
$46.4M
NSTN National Clinical Coordinating CenterU01NS086872 · NINDS · UNIVERSITY OF CINCINNATI · PI Joseph Paul Broderick, Pooja Khatri · 2013 to 2026
$32.3M
Making Acute Stroke Trials Succeed: Challenges and Potential SolutionsU01NS110772 · NINDS · UNIVERSITY OF CINCINNATI · PI Joseph Paul Broderick, Jordan J. Elm · 2020 to 2026
$24.3M
Hemostasis, Hematoma Expansion, and Outcomes After Intracerebral HemorrhageR01NS110779 · NINDS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI NAIDECH, ANDREW M · 2019 to 2023
$3.3M
NINDS NIH HHS R01 NS110779NINDS NIH HHS U01 NS044364NINDS NIH HHS U01 NS086872NINDS NIH HHS U01 NS110772
6 · The paper itself

Abstract

backgroundIntracerebral hemorrhage (ICH) is the deadliest form of stroke. In observational studies, lower serum magnesium has been linked to more hematoma expansion (HE) and intracranial hemorrhage, implying that supplemental magnesium sulfate is a potential acute treatment for patients with ICH and could reduce HE. FAST-MAG (Field Administration of Stroke Therapy - Magnesium) was a clinical trial of magnesium sulfate started prehospital in patients with acute stroke within 2 hours of last known well enrolled. CT was not required prior to enrollment, and several hundred patients with acute ICH were enrolled. In this ancillary analysis, we assessed the effect of magnesium sulfate treatment upon HE in patients with acute ICH.

methodsWe retrospectively analyzed data that were prospectively collected in the FAST-MAG study. Patients received intravenous magnesium sulfate or matched placebo within 2 hours of onset. We compared HE among patients allocated to intravenous magnesium sulfate or placebo with a Mann-Whitney

resultsAmong 268 patients with ICH meeting study entry criteria, mean 65.4±13/4 years, 33% were female, and 211 (79%) had a history of hypertension. Initial deficit severities were median (interquartile range) of 4 (3-5) on the Los Angeles Motor Scale in the field and National Institutes of Health Stroke Scale score of 16 (9.5-25.5) early after hospital arrival. Follow-up brain imaging was performed a median of 17.1 (11.3-22.7) hours after first scan. The magnesium and placebo groups did not statistically differ in hematoma volume on arrival, 10.1 (5.6-28.7) versus 12.4 (5.6-28.7) mL (

conclusionsMagnesium sulfate did not reduce HE or improve functional outcomes at 90 days. A benefit for patients with initial hypomagnesemia was not addressed. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT00059332.

Indexed as

Magnesium SulfateStrokeCerebral HemorrhageFemaleHematomaHumansMagnesiumMaleRetrospective StudiesUnited StatesMagnesiumMagnesium Sulfatehematomahemorrhagehypertensionmagnesiumserum

Identifiers

PMID35380053
PMCPMC9038696
OpenAlexW4224940910

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.